D
Zura Bio Limited ZURA
$3.51 -$0.21-5.65% NASDAQ
Recommendation
Prev Close
$3.72
Volume
309,720
Avg Vol (90D)
1,266,109
Market Cap
$241.89M
Dividend & Yield
--
52-Week Range
$0.97 - $4.68
P/E (TTM)
--
EPS (TTM)
-$0.67
My Lists My Alerts
Access our Premium Ratings
Get Access
Rating
Reward
Risk
Rating Factors
Growth Index
Efficiency Index
Solvency Index
Total Return Index
Volatility Index
Dividend Index
Headlines
Alberta Investment Management Corp Buys Shares of 133,200 Zura Bio Limited $ZURA
11/18/2025 - MarketBeat
Chardan Capital Reiterates Buy Rating for Zura Bio (NASDAQ:ZURA)
11/16/2025 - MarketBeat
Zura Bio Limited (NASDAQ:ZURA) Given Average Rating of "Moderate Buy" by Brokerages
11/16/2025 - MarketBeat
Wall Street Zen Downgrades Zura Bio (NASDAQ:ZURA) to Sell
11/16/2025 - MarketBeat
Chardan Capital Maintains Zura Bio (ZURA) Buy Recommendation
11/15/2025 - Nasdaq News: Stocks
Zura Bio (NASDAQ:ZURA) Issues Earnings Results
11/14/2025 - MarketBeat
Zura Bio (ZURA) Receives a Buy from Guggenheim
11/14/2025 - TipRanks Financial Blog
Zura Bio Limited Reports Third Quarter 2025 Results
11/14/2025 - TipRanks Financial Blog
Zura Bio (NASDAQ:ZURA) Issues Earnings Results
11/13/2025 - Ticker Report
Zura Bio Reports Third Quarter 2025 Financial Results and Recent Corporate Updates
11/13/2025 - GuruFocus
Zura Bio reports Q3 EPS (21c), consensus (18c)
11/13/2025 - The Fly
Zura Bio Reports Third Quarter 2025 Financial Results and Recent Corporate Updates
11/13/2025 - Business Wire
Zura Bio initiated with bullish view at Clear Street, here's why
11/12/2025 - The Fly
Zura Bio (NASDAQ:ZURA) Rating Increased to Hold at Wall Street Zen
11/9/2025 - MarketBeat
Wall Street Zen Upgrades Zura Bio (NASDAQ:ZURA) to "Hold"
11/8/2025 - Ticker Report
Zura Bio (ZURA) to Release Earnings on Thursday
10/30/2025 - MarketBeat
Zura Bio And 2 Other Promising Penny Stocks For Your Watchlist
10/28/2025 - Simply Wall St
Analysts Set Zura Bio Limited (NASDAQ:ZURA) Target Price at $11.60
10/28/2025 - Ticker Report
Zura Bio Limited (NASDAQ:ZURA) Sees Significant Growth in Short Interest
10/18/2025 - MarketBeat
Zura Bio's (ZURA) Sell (D-) Rating Reiterated at Weiss Ratings
10/14/2025 - MarketBeat
Zura Bio slips after CEO announces medical leave
10/10/2025 - SeekingAlpha.com: All News
Zura Bio slips after CEO announces medical leave
10/10/2025 - Seeking Alpha - Healthcare
Does Zura Bio's (ZURA) Severance Plan Reflect Management's Priorities Amid Cash Burn Pressures?
10/4/2025 - Simply Wall St
Zura Bio (NASDAQ:ZURA) Earns Buy Rating from Chardan Capital
10/3/2025 - Ticker Report
Zura Bio Implements Executive Severance Benefit Plan
9/30/2025 - TipRanks Financial Blog
Income Statement
Total Revenue (TTM)
--
EBITDA (TTM)
-$72.53M
EBIT (TTM)
-$72.57M
Net Income (TTM)
-$65.10M
Balance Sheet
Total Assets (Q)
$143.94M
Total Debt (Q)
$0.00
Total Liabilities (Q)
$25.49M
Book Value Per Share (Q)
$1.66
Cash Flow
Cash from Operations (TTM)
-$53.36M
Cash from Investing (TTM)
-$141.00K
Cash from Financing (TTM)
$4.30M
Net Change in Cash (TTM)
-$49.20M
Filings
Filing Date
Thursday, November 13, 2025
Period Date
Tuesday, September 30, 2025
Next Filing
Week of Mar 23 and 27 (est)
Price History
Loading...
Beta
1.38
7-Day Total Return
-4.36%
30-Day Total Return
4.15%
60-Day Total Return
58.82%
90-Day Total Return
114.02%
Year to Date Total Return
49.36%
1-Year Total Return
25.36%
2-Year Total Return
-26.11%
3-Year Total Return
-65.49%
5-Year Total Return
--
52-week Low
Apr 04, 2025 - $0.97
52-week High
Nov 12, 2025 - $4.68
Valuation
Market Cap
$241.89M - Micro Cap
Enterprise Value
$113.07M
Price/Sales (TTM)
--
Price/Book (Q)
2.23
Dividends and Shares
Shares Outstanding
94.56
Dividend Per Share (Most Recent)
--
Dividend Per Share (TTM)
--
Corporate Info
Website
zurabio.com
Phone Number
702 825 9872
Address
1489 W. Warm Springs Road
Henderson, NV 89014
Country
United States
Year Founded
2022
Business Description
Sector
Health Care
Industry
Pharmaceuticals, Biotechnology and Life Sciences
Zura Bio Limited, a clinical-stage biotechnology company, develops medicines for immune and inflammatory disorders in the United States. The company develops Tibulizumab, an immunoglobulin... more
NASDAQ 12/02/2025 4:00PM Eastern Quotes delayed